Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gynecological Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1609952

This article is part of the Research TopicAdvances in Diagnosis and Treatment of Endometrial CancerView all 5 articles

Adenomyosis-Associated Differences in Clinicopathological features and Survival Outcomes in endometrial cancer: A meta-analysis

Provisionally accepted
Xueyang  PeiXueyang Pei1Yafeng  ZhengYafeng Zheng2Xin  ZuoXin Zuo1Shuang  WuShuang Wu3Yejuan  JiangYejuan Jiang1Liang  YuLiang Yu4*
  • 1Yixing People's Hospital, Yixing, Jiangsu, China
  • 2Changzhou No.2 People's Hospital, Changzhou, Jiangsu Province, China
  • 3Baoying People's Hospital, Jiangsu, China
  • 4Nanjing Medical University, Nanjing, China

The final, formatted version of the article will be published soon.

Objective: To systematically assess whether coexisting adenomyosis modifies the clinicopathological phenotype and prognostic trajectory of endometrial carcinoma.Methods A comprehensive literature search was conducted in PubMed, Web of Science, Wanfang, CNKI, and VIP databases from inception to March 1, 2025, to identify observational studies (cohort/case-control) evaluating the impact of coexisting adenomyosis on clinicopathological features and survival outcomes in endometrial cancer. Statistical analysis was conducted via Stata 18.0 and R software.A total of 36 studies were included. The pooled analysis demonstrated that compared with the control group (SEC), endometrial carcinoma patients with coexisting adenomyosis (ECA) exhibited significantly lower incidence of lymphovascular invasion, lower risks of ascites positivity, cervical involvement, lymph node metastasis and distant metastasis, higher proportion of superficial myometrial invasion and endometrioid subtype, earlier FIGO staging, lower tumor grades, higher ER/PR positivity and better prognosis(all P < 0.05). Conversely, No significant associations were observed for adnexal metastasis, or molecular markers (dMMR, TP53 mutations, all P > 0.05).This meta-analysis provides preliminary evidence suggesting that coexisting adenomyosis may potentially attenuate endometrial cancer progression through multifactorial mechanisms. Therefore, adenomyosis status might warrant consideration for integration into prognostic models and treatment decision-making algorithms in the future.

Keywords: endometrial cancer, Adenomyosis, prognosis, Meta-analysis, Gynecologic neoplasms

Received: 11 Apr 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Pei, Zheng, Zuo, Wu, Jiang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Liang Yu, Nanjing Medical University, Nanjing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.